Abstract
Results from a landmark study have shown that the ACE inhibitor ramipril prevents major cardiovascular events in patients with a history of vascular disease or diabetes mellitus. The Heart Outcomes Prevention Evaluation (HOPE) trial showed that ramipril reduces the risk of cardiovascular mortality, stroke or myocardial infarction (MI) by 22% in this patient group. Results were presented at the 21st Congress of the European Society of Cardiology [Barcelona, Spain; August-September 1999], where HOPE investigators said that the study represents one of the greatest discoveries in heart disease treatment worldwide.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
